New Delhi: Centre’s panel has recommended against allowing Serum Institute of India to conduct phase two and three clinical trials of Covavax Covid-19 vaccine on children in 2-17 years age group.
According to sources, the government panel has asked the Serum Institute (SII) to complete trials on adults first. The SII hopes to introduce US firm Novavax’s Indian version of the Covid-19 vaccine – ‘Covavax’ by September this year and start trials on children from July.
The SII applied to the Drugs Controller General of India (DCGI) on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.
